Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 4/20 | 0.83 |
| ▸ | CSF1R | P07333 | 5/20 | 0.60 |
| ▸ | PDGFRB | P09619 | 5/20 | 0.60 |
| ▸ | FLT3 | P36888 | 5/20 | 0.60 |
| ▸ | FLT4 | P35916 | 1/20 | 0.60 |
| ▸ | PDGFRA | P16234 | 11/20 | 0.59 |
| ▸ | KIT | P10721 | 2/20 | 0.59 |
| ▸ | RET | P07949 | 1/20 | 0.58 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.58 |
| ▸ | KDR | P35968 | 12/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4548867 | 0.93 | MET (0.96) | METCSF1RPDGFRBFLT3FLT4 | |
| SCHEMBL2747758 | 0.91 | MET (1.00) | METCSF1RPDGFRBFLT3FLT4 | |
| SCHEMBL22972326 | 0.88 | MET (0.72) | METCSF1RPDGFRBFLT3FLT4 | |
| SCHEMBL4548861 | 0.85 | MET (0.71) | METCSF1RFLT4PDGFRAKDR | |
| SCHEMBL4548860 | 0.84 | MET (0.80) | METFLT3PDGFRAKITKDR | |
| SCHEMBL2748085 | 0.84 | MET (0.75) | METCSF1RPDGFRBFLT3PDGFRA | |
| SCHEMBL22104195 | 0.83 | MET (0.77) | METCSF1RPDGFRBFLT3FLT4 | |
| SCHEMBL2747522 | 0.83 | MET (0.73) | METFLT3PDGFRAKITKDR | |
| SCHEMBL21301531 | 0.83 | MET (0.85) | METCSF1RPDGFRBFLT3FLT4 | |
| SCHEMBL31324673 | 0.83 | MET (0.85) | METCSF1RPDGFRBFLT3FLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178557-B2 | Compounds and methods of use | AMGEN INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-8178557-B2 | Compounds and methods of use | AMGEN INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-20090176774-A1 | Compounds and methods of use | AMGEN INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-20090176774-A1 | Compounds and methods of use | AMGEN INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-7435823-B2 | Compounds and methods of use | AMGEN INC. (US) | 2008-10-14 | — | — | US | disclosed |
| US-7435823-B2 | Compounds and methods of use | AMGEN INC. (US) | 2008-10-14 | — | — | US | disclosed |
| US-7435823-B2 | Compounds and methods of use | AMGEN INC. (US) | 2008-10-14 | — | — | US | disclosed |
| US-20060241115-A1 | Compounds and methods of use | AMGEN INC. | 2006-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241115-A1 | Compounds and methods of use | HGF, HGFAC, MET | MET 3/4885CSF1R 237/4885PDGFRB 28/4885 |
| US-20090176774-A1 | Compounds and methods of use | HGF, HGFAC, MET | MET 3/4885CSF1R 237/4885PDGFRB 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.